Strata Oncology expands Strata PATH trial to eight Sarah Cannon Research Institute sites

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Sarah Cannon Research Institute joined Strata Oncology Inc.’s Precision Indications for Approved THerapies (NCT05097599) trial. Researchers will enroll patients at eight SCRI-affiliated sites including:

Florida Cancer Specialists (4 sites)Genesis Cancer and Blood Institute, Hot Springs, ARHematology Oncology Clinic, Baton Rouge, LATennessee Oncology, Chattanooga, TNZangmeister Cancer Center, Columbus, OH

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login